Sarepta shares fall 37% as FDA questions future of key gene therapy

Sarepta Therapeutics shares plummeted nearly 37% after reports indicated the FDA is considering halting shipments and potentially withdrawing its flagship gene therapy, Elevidys, following multiple patient deaths and prior efficacy concerns. This regulatory scrutiny is critical for Sarepta, as Elevidys constitutes over half its revenue, leading analysts to warn that its removal would severely threaten the company's viability and survival.

Analysis

Sarepta Therapeutics is facing an existential crisis following reports that the U.S. Food and Drug Administration is considering halting shipments and potentially revoking market approval for its flagship gene therapy, Elevidys. This regulatory scrutiny, prompted by several patient deaths linked to the therapy's delivery mechanism, triggered a nearly 37% single-day stock collapse, contributing to an 87% year-to-date decline. The situation is critical as Elevidys accounts for over half of the company's net product revenue. The drug's regulatory history was already tenuous, having received expanded approval despite failing its primary Phase 3 endpoint, a decision now under renewed scrutiny. Analyst sentiment has turned sharply negative, with Baird downgrading the stock to Neutral with a $15 price target and BMO Capital Markets warning that a full withdrawal of Elevidys would mean "Sarepta is done." While the company projects it could still generate $500 million annually from a limited patient population, this potential revenue is overshadowed by the imminent risk of a complete market withdrawal, making the FDA's next move the single most important determinant of the company's viability.

Key Decisions for Investors

• Investors should recognize the binary, high-risk nature of this event-driven situation, as the company's survival is directly dependent on the FDA's decision regarding Elevidys.
• Given the extreme negative sentiment and the fundamental threat to over half of the company's revenue, maintaining or initiating a long position carries a significant risk of further capital loss.
• Closely monitor all official communications from the FDA, as a formal request to halt or withdraw Elevidys will be the primary catalyst determining the stock's future trajectory.
• Consider the Baird downgrade and $15 price target as a key valuation benchmark, reflecting the severe impairment to Sarepta's commercial prospects even in a best-case scenario where the drug remains on the market for a limited patient group.